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OBJECTIVE — To systematically evaluate the association between serum uric acid (SUA)
level and subsequent development of type 2 diabetes.
RESEARCH DESIGN AND METHODS — We searched Medline (31 March from 1966
to 2009) and Embase (31 March from 1980 to 2009) for observational cohort studies examining
theassociationbetweenSUAandtheriskoftype2diabetesbymanualliteraturesearch.Relative
risks (RRs) for each 1 mg/dl increase in SUA were pooled by using a random-effects model. The
studies included were stratiﬁed into subgroups representing different study characteristics, and
meta-regression analyses were performed to investigate the effect of these characteristics on the
association between SUA level and type 2 diabetes risk.
RESULTS — The search yielded 11 cohort studies (42,834 participants) that reported 3,305
incident cases of type 2 diabetes during follow-up periods ranging from 2.0 to 13.5 years. The
pooled RR of a 1 mg/dl increase in SUA was 1.17 (95% CI 1.09–1.25). Study results were
consistently signiﬁcant (i.e., 1) across characteristics of participants and study design. Publi-
cation bias was both visually and statistically suggested (P  0.03 for Egger’s test, 0.06). Ad-
justmentforpublicationbiasattenuatedthepooledRRpermg/dlincreaseinSUA(RR1.11[95%
CI 1.03–1.20]), but the association remained statistically signiﬁcant (P  0.009).
CONCLUSIONS — The current meta-analysis suggests that SUA level is positively associ-
ated with the development of type 2 diabetes regardless of various study characteristics. Further
research should attempt to determine whether it is effective to utilize SUA level as a predictor of
type 2 diabetes for its primary prevention.
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I
dentifying risk factors for the develop-
ment of type 2 diabetes is essential for
its early screening and prevention. Se-
rum uric acid (SUA) level has been sug-
gested to be associated with risk of type 2
diabetes. Biologically, uric acid (UA)
plays an important role in worsening of
insulin resistance in animal models by in-
hibiting the bioavailability of nitric oxide,
which is essential for insulin-stimulated
glucoseuptake(1).However,hyperinsu-
linemia as a consequence of insulin
resistance causes an increase in SUA con-
centration by both reducing renal UA se-
cretion (2) and accumulating substrates
for UA production (3). Therefore, it re-
mains controversial whether SUA is
independently associated with the devel-
opmentoftype2diabetes.Theaimofour
meta-analysis was to summarize the asso-
ciationbetweenSUAlevelandriskoftype
2 diabetes derived from previously pub-
lished cohort studies and to examine the
effect of study characteristics on this
association.
RESEARCH DESIGN AND
METHODS
Search strategy
The meta-analysis was fundamentally
conducted according to the checklist of
the Meta-analysis of Observational Stud-
ies in Epidemiology (4). We performed a
systematic literature search of Medline
(31 March from 1966 to 2009) and Em-
base (31 March from 1980 to 2009) for
observational cohort studies examining
the association between SUA level and
risk of type 2 diabetes. The key words
were related to UA (combined exploded
version of the medical subject headings
[MeSH] [uric acid] and the following text
words: hyperuricemia OR [acid AND
uric] OR trioxopurine OR trihydroxypu-
rineORurateORgoutORgouts)andtype
2 diabetes (combined unexploded ver-
sion of MeSH [diabetes OR diabetes, type
2] and the following text words [hyper-
glycemias OR hyperglycemia OR [diabe-
tes mellitus AND {type 2 OR type II OR
ketosis resistant OR ketosis-resistant OR
maturity onset OR maturity-onset OR
noninsulindependentORnoninsulinde-
pendent OR non-insulin-dependent OR
slow onset OR slow-onset OR stable OR
adult onset OR adult-onset}] OR MODY
OR type 2 diabetes).
Included reports had to meet the fol-
lowing criteria: 1) prospective or histori-
cal cohort study, 2) inclusion of type 2
diabetes as a speciﬁed outcome, 3) base-
lineassessmentofSUAlevel,and4)inclu-
sion of data on relative risk (RR), which is
generally expressed as the odds ratio in a
historical cohort study or the risk ratio in
a prospective cohort study, and its corre-
sponding 95% CIs (or data to calculate
them) for type 2 diabetes associated with
SUA level. When two or more studies
were conducted using the same subjects,
the study that included the most recently
updated data was selected.
Data abstraction
The data that we abstracted included the
ﬁrst author’s name, year of publication,
countryoforigin,cohortdesign(i.e.,pro-
spectiveorhistoricalcohort),methodsfor
ascertaining diabetes, mean follow-up
duration, mean or midpoint of partici-
pants’ age, proportion of men, baseline
SUA level, number of participants and
events, and adjusted variables. Odds and
risk ratios were combined as indicators of
RR, based on the assumption that the
odds ratio is an approximation of the risk
ratio; this assumption has some limita-
tions, however, especially when the out-
come of interest is common (5).
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as unadjusted and adjusted RRs, the most
completely adjusted RR was used. Each
RR was transformed to its natural loga-
rithm (log RR), and its corresponding
95% CI or P value was used to calculate
the SE for each log RR. Two of our inves-
tigators independently reviewed each
published article and extracted the rele-
vant information. Any disagreement was
resolved by consensus.
Data synthesis
To quantify the dose-response relation-
ship between the baseline SUA level and
risk of type 2 diabetes, we calculated the
RR for each 1 mg/dl increase in SUA in
eachstudy.ForstudiesthatanalyzedSUA
level not as a continuous but as a categor-
ical variable (i.e., studies where subjects
were categorized based on SUA level and
RRs for the development of type 2 diabe-
tesaccordingtoSUAlevelwerereported),
we used the method for trend estimation
supportedbyBerlinetal.(6)andOrsiniet
al. (7). This method is particularly useful
when the full data are not available. It en-
ables us to correct for covariance between
risk estimates from the same study and to
estimate the corrected linear trend using
generalized least squares if data on the
adjusted RR and the number of partici-
pants (or person-time) and cases for each
category are provided.
When the mean SUA level was not
reported, the range’s midpoint in each
category was used, except for the lowest
and highest category, for which the mean
SUAlevelwasestimatedbyassumingnor-
mality of SUA distribution, which is the
samemethodasusedinapreviouslypub-
lished meta-analysis (8). Each log RR was
pooled by using a random-effects model
(9). The overall RR and its 95% CI could
be calculated by exponentiation of the
pooledlogRR.Weassessedheterogeneity
of RRs across studies using both I
2 and Q
statistics (10).
Sensitivity analyses
The studies included were stratiﬁed by
key factors related to cohort design (i.e.,
prospective or historical cohort) and
other study properties related to study
quality and participant characteristics
thatwereidentiﬁedapriori.Studyquality
was assessed according to the method of
ascertainment of diabetes (whether blood
measurements, or reports by participants
or physicians, or both), mean follow-up
duration (8o r8 years), and inclusion
of adjustment for the following poten-
tially important confounding variables:
alcohol intake (yes or no) and metabolic
proﬁle (sufﬁcient or insufﬁcient). We re-
garded the adjustment for metabolic vari-
ables as sufﬁcient when the risk estimate
was adjusted for more than three factors
among obesity, hypertension (or systolic
blood pressure), fasting plasma glucose,
HDL cholesterol, and triglycerides. We
identiﬁed country of origin (Asian or
Western countries), mean age (50 or
50 years), sex (whether men only,
women only, or both men and women),
and mean SUA level (5.5 or 5.5 mg/
dl) as possible participant characteristics.
We calculated the pooled RR within the
strata of each study characteristic, and
meta-regression analyses were conducted
to assess the effects of these study charac-
teristics on the type 2 diabetes risk and
incremental increase in SUA level.
The possibility of publication bias
wasassessedbytheBegg’sandtheEgger’s
tests (11,12) and visual inspection of a
funnel plot. We also performed the Duval
and Tweedie “trim-and-ﬁll” procedure
(13)tofurtherassessthepossibleeffectof
publication bias in our meta-analysis.
This method considers the possibility of
hypothetical “missing” studies that might
exist, imputes their RRs, and recalculates
a pooled RR that incorporates the hypo-
theticalmissingstudiesasthoughtheyac-
tually existed. Data were analyzed by
Table 1—Characteristics of studies included in meta-analysis
First author Year
Cohort
designation Population
Follow-up
(years)
Diabetes
ascertainment*
Baseline
SUA
(mg/dl)
Age
(years)
%
Men
Number of
participants†
Number
of cases
Cohort
design
Medalie (15) 1975 IIHDS Israel 5.0 Both 4.8 49 100 8,688 344 H
Ohlson (16) 1988 SMB Sweden 13.5 Both 5.3 50 100 766 47 H
Perry (17) 1995 BRHS British 12.8 Report 6.0 50 100 7,577 194 P
Chou (18) 1998 KS China 2.0 Measure 5.8 50 52 654 39 H
Taniguchi (19) 2001 OHS Japan 9.5 Measure 5.2 41 100 6,478 639 P
Meisinger (20) 2002 MONIKA Germany
Men 7.6 Report 5.7 52 100 3,052 128 H
Women 4.0 51 0 3,114 85 H
Lin (21) 2004 KS China 7.0 Both
Men 8.0 49 100 293 27 H
Women 7.1 55 0 161 21 H
Chien (22) 2008 CSCCC China 9.0 Measure 5.6 54 43 2,690 548 H
Dehghan (23) 2008 RS the Netherlands 10.1 Both 5.4 over 55 NA 4,536 462 P
Nan (24) 2008 MNCDS Mauritius 8.2 Both
Men 6.6 41 100 1,941 337 H
Women 5.0 42 0 2,318 379 H
Kramer (25) 2009 UC U.S. 13.0 Measure 5.7 63 41 566 55 H
*Measure  using blood measurements, report  using reports by participants or physicians, and both  using both blood measurements and reports by
participantsorphysicians.†Numberofparticipantsincludedintheanalysisineachstudy(notnecessarilythenumberofparticipantsatthebeginningofeachstudy).
BRHS,BritishRegionalHeartStudy;CSCCC,Chin-ShanCommunityCardiovascularCenter;H,historicalcohort;IIHDS,IsraelIschemicHeartDiseaseStudy;JAPF,
Japan Arteriosclerosis Prevention Fund; KS, The Kinmen Study; MNCDS, Mauritius Non-Communicable Diseases Surveys; MONIKA, MONIKA-Augsberg Cohort
Study; NA, not available; OHS, The Osaka Health Study; P, prospective cohort; RS, The Rotterdam Study; SMB, The Study of Men Born in 1913; UC, Universityo f
California.
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College Station, TX). P  0.05 was con-
sidered as statistically signiﬁcant except
for the test of publication bias, in which
the level of signiﬁcance is P  0.10 (14).
RESULTS
Literature search
Of 1,258 citations retrieved by the search
strategy, 1,225 citations were excluded
after a ﬁrst screening based on titles and
abstracts, leaving 33 articles for full-text
review. Manual searching of the reference
lists of these articles identiﬁed 8 addi-
tional articles. Of 41 articles for full-text
review, 30 articles were excluded for the
following reasons: 1) they were case-
control studies (6 studies); 2) they were
clinical trials (3 studies); 3) risk estimates
of the association of type 2 diabetes with
SUA level were not reported (9 studies);
4) prespeciﬁed outcome did not include
type 2 diabetes (5 studies), and sufﬁcient
data to estimate the RR of type 2 diabetes
and its corresponding SE per incremental
increaseinUAwerenotprovided(4stud-
ies);and5)datareportedwereupdatedby
more recent studies (3 studies). Eleven
studies(15–25)mettheinclusioncriteria.
Three studies investigated men and
women separately. Finally, 14 cohorts in-
volving a total of 42,834 participants and
3,305incidentcaseswereincludedinour
analyses.
Study characteristics
Characteristics of the 11 included studies
are shown in Table 1. Three studies
(17,19,23) were prospective cohort and
eight studies (15,16,18,20–22,24,25)
were historical cohort. The selected stud-
ies were published between 1975 and
2009, and the number of subjects per
study ranged from 250 to 8,688. Mean
SUA level of subjects ranged from 4.0 to
8.0 mg/dl, and mean age ranged from 41
to 63 years except for one study (23), in
whichdataonmeanage(55years)were
notavailable.Fourstudies(15–17,19)in-
cluded men only, and seven studies (18–
21,23–25) included both women and
men. Six studies (15,18,19,21,22,24)
were conducted in Asian countries and
ﬁve studies (16,17,20,23,25) in Western
countries. Mean follow-up duration
ranged from 2.0 to 13.5 years.
Regarding methods for ascertaining
diabetes, four studies (18,19,22,25) used
blood measurements only, two (17,20)
used reports by participants and/or phy-
sicians only, and ﬁve (15,16,21,23,24)
used both. Risk measures were adjusted
for alcohol intake in ﬁve studies
(17,19,20,22,24), and the adjustment for
sufﬁcient metabolic variables was sufﬁ-
cient in ﬁve studies (18,21–24). A few
risk estimates were adjusted for smoking
status (three studies) (17,19,20), family
history of diabetes (four studies)
(16,20,22,24), and fasting insulin con-
centration (three studies) (18,21,24).
Only two studies (21,24) considered the
effect of serum creatinine, and one study
(25) considered the effect of diuretic use.
None of risk measurements was adjusted
for other drugs that inﬂuence SUA level
such as alloprinol.
Overall and stratiﬁed analyses
Figure 1 shows a forest plot with RRs and
95% CIs and pooled estimates for the re-
duction in risk of type 2 diabetes for each
Figure 1—Overall RR (with corresponding 95% CIs) for risk of type 2 diabetes for each mg/dl increase in SUA. The area of each square is
proportional to study weight. Diamond indicates overall RR; horizontal lines indicate 95% CIs.
Kodama and Associates
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RR(95%CI)was1.17(1.19–1.25).There
was evidence of statistical heterogeneity
of RRs across studies (Q statistic, 50.4; I
2
statistic, 74.2%; P  0.001).
Table 2 shows ﬁndings of the strati-
ﬁed and meta-regression analysis to ex-
plore the effects of study characteristic.
An increased risk of type 2 diabetes asso-
ciated with an incremental increase in
SUA was consistently found within all
strata of each study characteristic (i.e., all
pooled RRs were 1). There were no sig-
niﬁcant differences in the pooled risk es-
timates between cohort design (pooled
RR [95% CI] of 1.22 [1.10–1.36] for his-
torical cohort and 1.10 [1.01–1.20] for
prospective cohort, P  0.36). The inﬂu-
ence of participant characteristics on the
study results was not signiﬁcant. Adjust-
ment for alcohol intake attenuated the as-
sociation between SUA and type 2
diabetes risk (P  0.02), whereas the ef-
fect of sufﬁcient adjustment for metabolic
variables was not signiﬁcant (P  0.46).
Test of publication bias
Visual inspection of the funnel plot re-
vealed asymmetry (see online appendix A
[available at http://care.diabetesjournals.
org/cgi/content/full/dc09-0288/DC1]). This
raises the possibility of publication bias,
which was statistically supported by the
Egger’s test (P  0.06). We decided to
adjust for this publication bias using the
trim-and-ﬁll method (13). According to
this method, it was suggested that there
were three hypothetical negative unpub-
lished cohorts that distorted the symme-
tryofthefunnelplot.Whenthesecohorts
wereincorporatedtoproduceahypothet-
ically symmetrical funnel plot, the associ-
ation between SUA and type 2 diabetes
was modestly attenuated (RR 1.10 [95%
CI 1.03–1.20]) but remained statistically
signiﬁcant (P  0.009).
CONCLUSIONS — Our meta-analy-
sis is the ﬁrst to summarize the quantita-
tive relationship between SUA level and
risk of type 2 diabetes, indicating that
each1mg/dlincreaseinSUAresultedina
17% increase in the risk of type 2 diabe-
tes. Table 3 compares other risk factors of
type 2 diabetes, established from meta-
analysis or systematic review (26–29),
with SUA. Interestingly, the effect of a 1
mg/dl increment in SUA has been found
to be comparable to a 1 kg/m
2 increment
in BMI.
Pathologically and epidemiologically,
it has been indicated that elevated SUA
concentration is correlated with lifestyle
factors(highalcoholintake[30]inpartic-
ular) and various metabolic proﬁles (es-
pecially high values of BMI, blood
pressure, fasting plasma glucose and trig-
lycerides,andlowHDLcholesterolvalues
[31,32],whicharetypicallyconsideredto
be diagnostic criteria for metabolic syn-
drome [33]). Therefore, it is possible to
establish whether the observed positive
association between SUA level and risk of
type2diabetesisnoncausal.Oursensitiv-
ity analysis indicated that a signiﬁcant as-
sociation was observed if analyses were
limited to studies that included adjust-
ment for alcohol intake or sufﬁcient met-
abolic confounders (i.e., more than three
metabolic confounders among BMI, fast-
ing plasma glucose, hypertension [or sys-
tolic blood pressure], HDL cholesterol,
and triglycerides), although the adjust-
ment weakened the association. There-
fore, the results of this analysis strongly
suggest that SUA is an independent pre-
dictor of the development of type 2 dia-
betes. Therefore, these ﬁndings suggest
that there are both noncausal and causal
associations between SUA level and the
risk of type 2 diabetes.
The limitations of this meta-analysis
must be considered. First, the overall ef-
fect estimated by the current analysis
mightbeinaccurateduetothestatistically
signiﬁcant publication bias. According to
the results of the compensatory trim-and-
ﬁll method, the overall RR of type 2 dia-
betes for each 1 mg/dl SUA increase
should be scaled downward by 0.07 to
Table2—Stratiﬁedandmeta-regressionanalysistoexploretheeffectsofstudycharacteristics
Number of
cohorts
Pooled RRs
(95% CI)*
P value of
meta-regression†
Study design
Historical cohort 10 1.22 (1.10–1.36) 0.55
Prospective cohort 4 1.10 (1.01–1.20)
Indicators of participant characteristics
Country
Asia 8 1.09 (1.04–1.21) 0.10
Western 6 1.27 (1.12–1.44)
Mean age (years)
50 8 1.12 (1.04–1.19) 0.14
50 6 1.26 (1.11–1.44)
Sex
Men only 7 1.09 (1.02–1.16) 0.09
Women only 4 1.28 (1.08–1.51) 0.31
Both men and women 3 1.40 (0.98–2.00)
Mean SUA level (mg/dl)
5.5 6 1.18 (1.15–1.32) 0.98
5.5 8 1.16 (1.05–1.28)
Indicators of study quality
Study adjustment for
alcohol intake
No 9 1.27 (1.13–1.43) 0.02
Yes 5 1.07 (1.02–1.12)
Metabolic confounders‡
Insufﬁcient 8 1.21 (1.09–1.34) 0.46
Sufﬁcient 6 1.11 (1.02–1.21)
Follow-up duration (years)
8 6 1.25 (1.03–1.51) 0.37
8 8 1.13 (1.05–1.20)
Diabetes ascertainment
Blood measurements only 4 1.18 (1.02–1.37) 0.81
Report only 3 1.24 (0.96–1.59) 0.64
Both 7 1.14 (1.06–1.23)
*PooledRRsoftype2diabetesforeach1mg/dlincreaseinSUAwithinthestrataofeachstudycharacteristic
are indicated. †Represents the test for signiﬁcance of the effect across strata. ‡If the RRs were adjusted for
morethanthreeconfounders(amongBMI,fastingplasmaglucose,hypertensionorsystolicbloodpressure,
HDL cholesterol, and triglycerides), they were regarded as sufﬁcient; otherwise, they were regarded as
insufﬁcient.
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method may overestimate the magnitude
of any publication bias (34). Moreover,
this method did not change the statistical
signiﬁcance of the association between
SUA level and development of type 2 di-
abetes.Therefore,theeffectofadjustment
forpublicationbiaswasprobablymodest.
Second, the odds and risk ratios were
combined as indicators of RR. The odds
ratio overestimates the risk ratio, espe-
cially when the outcome of interest is
common. It is possible that this method
could distort the overall and stratiﬁed
analyses within cohort design. The over-
estimation is, however, of little practical
importance and can be ignored as long as
the pooled risk ratio is near to 1 and the
total incidence is relatively rare (10%),
as they were in our meta-analysis (5).
Third, in the sensitivity analysis, the
statisticalpowermightbeinsufﬁcientto
explain the source of the large study
heterogeneity because of the small
number of data units within strata. For
example, there was a substantially
larger increase in the risk of elevated
SUA for development of type 2 diabetes
observed in Western countries (RR
1.27) compared with Asian countries
(RR 1.09) and for women (RR 1.28)
compared with men (RR 1.09). Al-
though these differences were statisti-
cally insigniﬁcant, we cannot exclude
thepossibilityoftheinﬂuenceofraceor
sex on the association between SUA
level and type 2 diabetes. This issue
might be solved by a patient-level meta-
analysis, which would be beyond the
current meta-analysis. Fourth, there
werefewstudiesthatincludedaconsid-
eration of signiﬁcant confounders inﬂu-
encing SUA level, such as serum
creatinine and drugs (e.g., diuretic
agents or alloprinol). These confound-
ers could contribute to modiﬁcation of
the association between SUA and risk of
type 2 diabetes. Fifth, we thought it was
tooearlytodeterminewhetherthereisa
cutoff level in SUA to increase or reduce
the risk of development of type 2 diabe-
tes because of both the limited number
of studies that used SUA level as a cate-
gorical variable and provided RR data
for each category and the variation in
methods of how SUA levels in each sub-
ject were categorized. Therefore, we
cannot rule out the possibility that SUA
level has a threshold effect on the risk of
type 2 diabetes rather than a dose-
response effect.
In conclusion, our meta-analysis sug-
gests that SUA level is independently as-
sociated with the development of type 2
diabetes. It is possible that these ﬁndings
are the ﬁrst step to utilizing SUA, which
has been suggested to be a risk factor for
type 2 diabetes, in primary care medical
practice. Further research should attempt
toinvestigatewhetherSUAwouldbeuse-
ful for predicting type 2 diabetes with re-
spect to the prevention of type 2 diabetes;
forexample,studiesshouldaimtospecify
the population for which the SUA level is
especiallyimportantandtodeterminethe
SUA threshold for increased risk of type 2
diabetes.
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